Markets have been buoyed by the news overnight that a Gilead Sciences-developed treatment for COVID-19 had yielded positive results.
Against this backdrop, we’ve provided a link to an article by Tim Xu, an investment associate at Arix Bioscience PLC (LON:ARIX), the venture capital company.
In it, he explores the “incredible diversity of tools biotech has called into the battle against coronavirus”.
READ: For Tim's article click on the link
"A viable therapeutic would dramatically change the tone of the COVID-19 pandemic, giving hope and a path to eradicating the virus, saving lives and livelihoods,” he writes.
As for the Gilead drug, the information in the market is at least one step removed from the source material.
An report in a publication called Stat suggests that more than one hundred severely ill patients taking part in the University of Chicago study showed rapid recovery from the condition.
The online news site obtained a video discussion about the trial, which quotes Kathleen Mullane, an infectious disease specialist who is leading the trials at the university hospital, as saying: “The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish.”